Loss of rap1GAP in papillary thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 3, 2009, Pages 1026-1032

  Nellore, Anoma ^a   Paziana, Karolina ^a   Ma, Changqing ^a   Tsygankova, Oxana M ^a   Wang, Yan ^a   Puttaswamy, Kanchan ^a   Iqbal, Ammarah U ^a   Franks, Susanna R ^a   Lv, Yu ^b   Troxel, Andrea B ^a   Feldman, Michael D ^a   Meinkoth, Judy L ^a   Brose, Marcia S ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Departments of Medicine Otorhinolaryngology: Head and Neck Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RAP1 PROTEIN; SMALL INTERFERING RNA;

ADENOMA; ALLELE; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; HYPERPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STAINING; THYROID CANCER;

RATTUS;

EID: 62349140432     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1042     Document Type: Article

References (32)

1. Bernards A, Settleman J 2004 GAP control: regulating the regulators of small GTPases. Trends Cell Biol 14:377
2. Gao Q, Srinivasan S, Boyer SN, Wazer DE, Band V 1999 The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol Cell Biol 19:733-744
3. Gao Q, Kumar A, Singh L, Huibregtse JM, Beaudenon S, Srinivasan S, Wazer DE, Band H, Band V 2002 Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 62:3315-3321
4. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K, Suzuki M, Itohara S, Nakahata T, Hiai H, Kawamoto H, Hattori M, Minato N 2003 Myeloproliferative stem cell disorders by deregulated Rap l activation in SPA-1-deficient mice. Cancer Cell 4:55
5. Tsygankova OM, Feshchenko E, Klein PS, Meinkoth JL 2004 Thyroid-stimulating hormone/cAMP and glycogen synthase kinase 3β elicit opposing effects on RaplGAP stability. J Biol Chem 279:5501-5507
6. Zhang L, Chenwei L, Mahmood R, van Golen K, Greetison J, Li G, D'Silva NJ, Li X, Burant CF, Logsdon CD, Simeone DM 2006 Identification of a putative tumor suppressor gene RaplGAP in pancreatic cancer. Cancer Res66:898-906
7. Tsygankova OM, Prendergast GV, Puttaswamy K, Wang Y, Feldman MD, Wang H, Brose MS, Meinkoth JL 2007 Downregulation of RaplGAP contributes to Ras transformation. Mol Cell Biol 27:6647-6658
8. Miller MJ, Prigent S, Kupperman E, Rioux L, Park S-H, Feramisco JR, White MA, Rutkowski JL, Meinkoth JL 1997 Ra1GDS functions in Ras- and cAMP-mediated growth stimulation. J Biol Chem 272:5600-5605
9. de Rooij J, Bos JL 1997 Minimal Ras-brnding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14:623-625
10. Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, Al-Khalili Szigyarto C, Persson A, Ottosson J, Wernerus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Ponten F, Uhlen M 200S A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics 7:2019-2027
11. Stork PJS 2003 Does Rapl deserve a bad Rap? Trends Biochem Sci 28:267
12. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63:4561-4567
13. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
14. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627
15. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22:4578-4580
16. Zhang Z, Mitra RS, Henson BS, Datta NS, McCauley LK, Kumar P, Lee JSJ, Carey TE, D'Silva NJ 2006 RaplGAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 168:585-596
17. Logsdon CD, Simeone DM, Binkley C, ArumugamT, GreensonJK, Giordano TJ, Misek DE, Hanash S 2003 Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63:2649-2657
18. Gupta V, Puttaswamy K, Lassoued W, Redlinger MA, Ransone K, Lee WF, Mandel SJ, Brose MS 2006 Early markers of biological response in a phase II study of sorafenib for metastatic thyroid carcinoma. Thyroid 16:1068
19. Cohen EEW, Rosen LS, Yokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR. Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
20. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O 'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
21. Sherman SI, Wirth LJ, Droz J-P, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun Y-N, Juan T, Stepan DE, Schlumberger MJ; the Mote-sanib Thyroid Cancer Study Group 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
22. Ribeiro-Neto F, Leon A, Urbani-Brocard J, Lou L, Nyska A, Altschuler DL 2004 cAMP-dependent oncogenic action of Rapl b in the thyroid gland. J Biol Chem 279:46868-46875
23. 1/S entry requires activated and phosphorylated Raplb. Pro Natl Acad Sci USA 99:5418-5423
24. Tanaka K, Inoue H, Miki H, Masuda E, Kitaichi M, Komaki K, Uyama T, Monden Y 1997 Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. Br J Cancer 76:594-599
25. Kooistra MRH,Dube N,Bos JL 2007 Rapl: a key regulator in cell-cell junction formation. J Cell Sci 120:17-22
26. Knox AL, Brown NH 2002 Rapl GTPase regulation of adherens junction positioning and cell adhesion. Science 295:1285-1288
27. Hogan C, Serpente N, Cogram P, Hosking CR, Bialucha CU, Feller SM, Braga VMM, Birchmeier W, Fujita Y 2004 Rapl regulates the formation of E-cad-herin-based cell-cell contacts. Mol Cell Biol 24:6690-6700
28. Boettner B, Govek E-E, Cross J, Van Aelst L 2000 The junctional multidomain protein AF-6 is a binding partner of the Rapl A GTPase and associates with the actin cytoskeletal regulator profilin. Proc Natl Acad Sci USA 97:9064-9069
29. Balzac F, Avolio M, Degani S, Kaverina I, Torti M, Silengo L, Small JV, Retta SF 2005 E-cadherin endocytosis regulates the activity of Rapl: a traffic light GTPase at the crossroads between cadherin and rntegrin function. J Cell Sci118:4765-4783
30. Weiss J, Rubinfeld B, Polakis PG, McCormickF, Cavenee WK, Arden KC 1994 The RAP1GA1 locus for human Rapl-GTPase activating protein 1 maps to chromosome 1p36-1p35. Cytogenetics, Cell Genetics 66:18-21
31. Nagai H, Negrini M, Carter SL, Gillum DR, Rosenberg AL, Schwartz GF, Croce CM 1995 Detection and cloning of a common region of loss of heterozygosity at chromosome lp in breast cancer. Cancer Res 55:1752-1757
32. Williamson C, Pannett AA, Pang JT, Wooding C, McCarthy M, Sheppard MN, Monson J, Clayton RN, Thakker RV 1997 Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome Ip35-p36. J Med Genet 34:617-619